Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amer M Zeidan

Showing results (1-10 of 313) with videos related to

Pageof 32
Sort By:
Expert Review of Hematology|March 10, 2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsMaximilian Stahl, Amer M Zeidan
Cells|July 27, 2022
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic SyndromesYasmin Abaza, Amer M Zeidan
Blood and Lymphatic Cancer : Targets and Therapy|July 9, 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]Amer M Zeidan, Eunice Wang
Cancer|February 14, 2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applicationsMaximilian Stahl, Amer M Zeidan
Blood Reviews|August 21, 2022
CHIPing away the progression potential of CHIP: A new reality in the makingZhuoer Xie, Amer M Zeidan
Expert Review of Hematology|April 12, 2017
Management of myelofibrosis: JAK inhibition and beyondMaximilian Stahl, Amer M Zeidan
Expert Opinion on Pharmacotherapy|March 10, 2026
Pharmacologic progress in higher-risk MDS: an uphill battleAlain Mina, Amer M Zeidan
Blood and Lymphatic Cancer : Targets and Therapy|July 9, 2025
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]Amer M Zeidan, Courtney DiNardo
Blood and Lymphatic Cancer : Targets and Therapy|June 27, 2025
Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]Amer M Zeidan, Sanam Loghavi
Expert Review of Hematology|October 8, 2013
Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Amer M Zeidan, Steven D Gore
Pageof 32

Showing results (1-10 of 313) with videos related to

Sort By:
Pageof 32
Expert Review of Hematology|March 10, 2017
Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trendsMaximilian Stahl, Amer M Zeidan
Cells|July 27, 2022
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic SyndromesYasmin Abaza, Amer M Zeidan
Blood and Lymphatic Cancer : Targets and Therapy|July 9, 2025
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]Amer M Zeidan, Eunice Wang
Cancer|February 14, 2017
Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applicationsMaximilian Stahl, Amer M Zeidan
Blood Reviews|August 21, 2022
CHIPing away the progression potential of CHIP: A new reality in the makingZhuoer Xie, Amer M Zeidan
Expert Review of Hematology|April 12, 2017
Management of myelofibrosis: JAK inhibition and beyondMaximilian Stahl, Amer M Zeidan
Expert Opinion on Pharmacotherapy|March 10, 2026
Pharmacologic progress in higher-risk MDS: an uphill battleAlain Mina, Amer M Zeidan
Blood and Lymphatic Cancer : Targets and Therapy|July 9, 2025
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]Amer M Zeidan, Courtney DiNardo
Blood and Lymphatic Cancer : Targets and Therapy|June 27, 2025
Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]Amer M Zeidan, Sanam Loghavi
Expert Review of Hematology|October 8, 2013
Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Amer M Zeidan, Steven D Gore
Pageof 32